GlassScriptPhysician profile
David Blackwell Jessup
NPI 1477502136
$3,700.39
in general payments reported to CMS, 2019-2025
28 companies · $2,387 in 2025
The $2,387 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $514 · 2020: $172 · 2021: $105 · 2022: $125 · 2023: $131 · 2024: $266 · 2025: $2,387.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,518 · Food and Beverage: $1,267.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,517.93 |
| Food and Beverage | $1,266.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,710.06 | 2025 | Micra |
| Abbott Laboratories | $521.49 | 2019-2025 | Aveir, Amplatzer Amulet, Jot Dx |
| Shockwave Medical, INC | $209.39 | 2021-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Novartis Pharmaceuticals Corporation | $154.07 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $123.92 | 2019-2022 | |
| Amgen INC. | $120.45 | 2019-2025 | Repatha |
| Biotronik INC. | $113.58 | 2024 | Biomonitor |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $107.33 | 2020-2025 | Lifevest |
| Pfizer INC. | $103.75 | 2019-2025 | |
| Abiomed | $73.16 | 2019-2024 | Impella |
| Philips North America LLC | $49.25 | 2021-2024 | (Br0) Coronary Atherectomy, (Br3) Coronary Other |
| Astrazeneca Pharmaceuticals LP | $48.30 | 2019-2023 | Farxiga |
| Sanofi-Aventis U.S. LLC | $43.13 | 2019 | |
| Boston Scientific Corporation | $39.37 | 2019 | |
| Cardiovascular Systems INC. | $38.44 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $34.81 | 2024 | Arcalyst |
| Cleerly, INC. | $27.63 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Asahi Intecc USA, INC. | $25.45 | 2025 | Asahi Coronary Wires |
| E.R. Squibb & Sons, L.L.C. | $23.17 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.13 | 2025 | |
| Scpharmaceuticals INC. | $19.58 | 2025 | |
| Daiichi Sankyo INC. | $17.98 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.46 | 2019 | |
| Terumo Medical Corporation | $15.95 | 2024 | Tr Band, Glidesheath Slender, Glidewire |
| Medtronic Vascular, INC. | $15.66 | 2019 | |
| Chiesi USA, INC. | $13.26 | 2020 | |
| Arbor Pharmaceuticals, INC. | $12.62 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Jessup listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.